CTOs on the Move

Anox Kaldnes Inc

www.kaldnes.com

 
Anox Kaldnes Inc is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.kaldnes.com
  • 58 Weybosset St
    Providence, RI USA 02903
  • Phone: 401.270.3898

Executives

Name Title Contact Details

Similar Companies

Gilva Biotechnology

Gilva Biotechnology is a Belmont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Translate Bio

Translate Bio is a leading mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Our proprietary mRNA therapeutic platform (MRTTM) is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. We believe that our MRTTM platform is applicable to a broad range of diseases caused by insufficient protein production or where production of proteins can modify disease, including diseases that affect the lung, liver, eye, central nervous system, lymphatic system and circulatory system. Our two lead programs are being developed as treatments for cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency.

Theralogix

Theralogix is a Holmes, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pfenex

We are a clinical stage development and licensing biotechnology company focused on leveraging our Pfenex Expression Technology™ platform to develop and improve protein therapies for unmet patient needs.

Generex

Generex Biotechnology has been engaged primarily in the research and development of drug delivery systems and technologies. Our primary focus has been our proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a handheld aerosol applicator. Generex Biotechnology has a two business focuses: 1) implementing an acquisition strategy and 2) financing sponsored clinical trials. We are positioning ourselves as a diversified holding company involved in increasing our "pipeline" of compounds, therapies, treatments, diagnostics, and technologies in all stages in the FDA process through accretive acquisitions. We are also strategically aligning ourselves with the global biopharmaceutical companies by providing a financing solution to them as sponsors of clinical trials, which are conducted by patient care providers (PCPs) such as hospitals, medical research institutes, centers, and clinics.